Technical Analysis for NAVB - Navidea Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.13 0.00% 0.00
NAVB closed unchanged on Friday, January 18, 2019, on 48 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NAVB trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Doji - Bullish? Reversal 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Narrow Range Bar Range Contraction -2.69%
Jan 16 Inside Day Range Contraction -2.69%
Jan 16 Wide Bands Range Expansion -2.69%
Jan 15 Doji - Bullish? Reversal -7.14%
Jan 15 Wide Bands Range Expansion -7.14%
Jan 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -7.14%
Jan 14 Wide Bands Range Expansion -7.14%

Older signals for NAVB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company's radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule investigational radiopharmaceutical that is used in lymphatic mapping procedures, which are performed to help stage breast cancer and melanoma; and NAV4694, an F-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer's disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; and RIGScan, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. It has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Is NAVB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.42
52 Week Low 0.1
Average Volume 597,706
200-Day Moving Average 0.2116
50-Day Moving Average 0.1608
20-Day Moving Average 0.1268
10-Day Moving Average 0.1364
Average True Range 0.0172
ADX 23.26
+DI 17.1679
-DI 13.2832
Chandelier Exit (Long, 3 ATRs ) 0.1034
Chandelier Exit (Short, 3 ATRs ) 0.1516
Upper Bollinger Band 0.1502
Lower Bollinger Band 0.1034
Percent B (%b) 0.57
BandWidth 36.908517
MACD Line -0.0059
MACD Signal Line -0.0093
MACD Histogram 0.0033
Fundamentals Value
Market Cap 21.06 Million
Num Shares 162 Million
EPS 0.48
Price-to-Earnings (P/E) Ratio 0.27
Price-to-Sales 3.31
Price-to-Book 4.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.15
Resistance 3 (R3) 0.15 0.14 0.14
Resistance 2 (R2) 0.14 0.14 0.14 0.14
Resistance 1 (R1) 0.14 0.14 0.14 0.14 0.14
Pivot Point 0.13 0.13 0.13 0.13 0.13
Support 1 (S1) 0.13 0.13 0.13 0.13 0.12
Support 2 (S2) 0.12 0.13 0.12 0.12
Support 3 (S3) 0.12 0.12 0.12
Support 4 (S4) 0.12